Participated · Series A · Nov 2025

Founded in 2021, Anzen provides retail insurance agents and brokers with an AI-powered distribution platform that automates submission intake, quote comparison, proposal creation, ACORD forms, loss-run retrieval, back-office tasks, compliance, renewals, and claims. The system gives users direct access to Specialty, Excess & Surplus, and standard P&C markets, positioning itself as an end-to-end operating system for commercial insurance placement. The company reports rapid growth to millions of dollars in annual recurring revenue, serves more than 5,000 retail agents nationwide, and processes thousands of submissions each month. To date, it has quoted hundreds of millions of dollars in premium through its platform, underscoring strong early product–market fit. Anzen plans to use new capital to deepen its AI workflows, expand carrier and agency-management-system integrations, and grow its team across functions. With $26 million raised so far, the company aims to cement its reputation as the first fully AI-native distribution platform capable of handling accounts of any size.

Participated · Equity · Aug 2025

Debut builds an AI-driven ingredient discovery platform to create scientifically-discovered, clinically-proven biotech ingredients and customizable formulations for skincare. The platform can screen upward of 50 billion ingredients and focuses on novel chemical entities that target the 14 hallmarks of aging. Debut's proprietary in-house skin health datasets have achieved 99% data consistency versus 85% in public datasets, improving its predictive capabilities. The company enables beauty brands to outsource formulation innovation at scale, reducing upfront R&D expenses. Debut plans to scale its formulation business in the US and enter Asia beginning in Singapore through partnerships with leading brands. Named one of TIME100 Most Innovative Companies 2025, Debut recently secured $20M to accelerate platform development and commercial expansion. Debut is a vertically integrated synthetic biology company based in San Diego, CA, focused on producing bio-based fragrance and cosmetic bioactive ingredients. Led by founder and CEO Joshua Britton, Ph.D., the company operates an integrated synthetic biology platform and advanced biomanufacturing approaches. Its platform aims to replicate the scent signature and precise characteristics of natural ingredients, including structurally complex and trace compounds that are difficult to source. Debut's advanced biomanufacturing is intended to enable fragrance brands to transition to bio-based formulas while protecting the olfactive integrity of their products. The company plans to use the funds to accelerate development of bio-identical and novel fragrance molecules, opening new creative possibilities for the fragrance industry. Debut Biotech has developed a proprietary cell-free biomanufacturing platform to produce rare, high-value and novel compounds and to improve traditional ingredient manufacturing. The platform has applications across food and wellness products, cosmetics, colors, therapeutics and other industrial uses. The company plans to commercialize ingredients developed on its platform using proceeds from the recent financing. To scale commercialization, Debut will expand into a 26,000 square foot facility in San Diego and triple the size of its team across San Diego and Atlanta. Those facility investments are intended to enable manufacturing to be done entirely in the United States. The company is led by CEO Joshua Britton. Debut Biotechnology develops a cell‑free biomanufacturing platform that combines custom‑designed immobilized enzymes with continuous processes to produce high‑value molecules for pharmaceutical and specialty chemical customers. Its plug‑and‑play enzyme cartridges enable transformation of bio‑renewable materials into therapeutics and specialty chemicals. The company has partnered with two large manufacturers to integrate its platform into existing pipelines. Debut plans to use new funding to support those integrations, expand business development, double its science team and create a pilot production system. The company was founded by Joshua Britton, Greg Wess and Brady Beauchamp and is a UC‑Irvine spinout.

Led · Equity · Jun 2024

Verituity provides an intelligent, verified payouts platform that enables smart B2B and B2C disbursements for banks and enterprises. Its platform verifies every payer, payee, account and transaction and uses advanced machine learning and AI models to power its Zero Trust Payout Verification™ and intelligent payments. The company says this minimizes risk, optimizes payout economics and ensures on-time digital payments to the right payee and payment account from the right funding account. Verituity is partnering with Mastercard Move to offer a white-label solution that enables secure, verified and near real-time payments for commercial banks and payers. The company plans to accelerate growth in banking and insurance and expand into mortgage servicing and energy. Management frames the product vision as eliminating checks and embedding verified, intelligent payouts into the fabric of business disbursements. Verituity offers a cloud-based, bank-grade platform that modernizes banks' treasury services and enables branded, verified digital payouts for business clients. Its platform unifies and automates identity verification, payment choice, payment account validation, risk and data compliance, and verified payment orchestration into a single web and mobile experience. By placing verification at the core of digital payouts, Verituity aims to reduce payout and compliance risks, lower operating costs, and enable banks to launch new revenue streams. The company targets use cases such as insurance claims, supplier payments, and merchant refunds where first-time and on-time payments are critical. Verituity plans to use new capital to expand go-to-market efforts and enhance its cloud-based verified digital payout platform. Headquartered in McLean, Va., it positions banks to compete more effectively with fintechs.

Participated · Equity · Jun 2024

Indico Data develops the Agentic AI platform, a solution that ingests and structures unstructured documents so insurers can automate core workflows such as underwriting, claims intake, and policy operations. Its technology helps carriers improve accuracy, speed, and compliance while lowering manual processing costs. The company has built a strong presence among North American property-and-casualty carriers and within the London Market, where it is viewed as a leader in insurance automation. Recent traction includes adoption by several top global insurers who deploy the platform to streamline the 'front door' of their operations. Indico positions itself as enabling the “agentic insurance enterprise,” allowing carriers to turn unstructured data into competitive advantage. Earlier in 2025, Guidewire made a strategic investment that further validated the company’s approach. Indico continues to deepen partnerships with major industry players to accelerate product development and market expansion.

Participated · Equity · Apr 2024

Lumeris operates as a value-based care managed services operator for health systems and providers, leveraging an AI-powered technology stack to collaborate with health systems and physician practices nationwide. It shares risk and operational responsibilities with providers to implement value-based models tailored to each population. Those models target Medicare Advantage, Traditional Medicare, Medicaid, and Commercial populations, aiming to improve quality metrics, enhance patient experience and physician satisfaction, and reduce total cost of care. The company is led by CEO Mike Long. Lumeris recently closed $100M in equity growth funding. It intends to use the funds to expand provider partnerships, including health systems and physician groups. Lumeris is a pioneer in population health management solutions. Through its operations, technology and consulting services, the company enables health care organizations to transition from volume- to value-based care. Its offerings help create Population Health Services Organizations, define populations for risk, and equip providers with process improvement strategies, technology tools, and clinical workflows. Lumeris also collaborates with payers to ensure appropriate contracts, measures and incentives are in place to influence physician behavior and drive quality, cost and utilization performance. A recent approximately $71 million private financing raised by its parent will be used to strengthen Lumeris’ market position and expand its value-based care solutions from eight to 20 U.S. markets. In its eight initial markets Lumeris has partnerships that provide services to 14 million consumers and expects to partner with organizations representing more than 50 million lives after the planned expansion. Essence Group (EGHC) operates through subsidiaries including Lumeris to deliver software, services and consulting for accountable health care. Lumeris supplies an integrated framework that delivers 22 core competencies through its Maestro, Maestro Plus and Tacklebox offerings. Maestro is described as an Enterprise Performance Management System that provides evidence-based decision support for payers, hospitals and physicians. The company says it built and tested its solutions for five years and measured results across hundreds of physicians and tens of thousands of patients. Most of the new capital from this financing will be invested in Lumeris to scale its accountable-care technologies and services. EGHC positions its offerings to help payers, hospitals and physician groups transition to value-driven, coordinated care.